COVID-19: For information related to COVID-19 (formerly referred to as “novel coronavirus"), visit

VCU Massey Cancer Center



Thousands of women with breast cancer may be spared chemotherapy, thanks to landmark study co-authored by Massey physician-researcher

Seventy percent of women with the most common type of newly diagnosed breast cancer can now be identified and safely skip chemotherapy, according to the results of a landmark 12-year clinical research study.

Continue reading →

Image of a series of skull CT scans on the wall [View Image]

Experimental drug combined with radiation selectively kills brain tumors in pre-clinical studies

A new study led by scientists at VCU Massey Cancer Center has shown that an experimental drug known as AZ32 selectively sensitizes brain tumors to radiation and significantly extends the survival of mouse models with human glioblastoma multiforme (GBM), the most common and deadly form of brain cancer. 

Continue reading →

Massey researcher Paul Fisher standing in his lab coat with his arms crossed [View Image]

New study points to a potential “Achilles heel” in brain cancer

Scientists at Virginia Commonwealth University believe they have uncovered an “Achilles heel” of glioblastoma multiforme (GBM), the most common and deadly form of brain cancer. Their study published this week in the Proceedings of the National Academy of Sciences details how a mechanism that protects glioma stem cells can potentially be exploited to develop new and more effective treatments for GBM.

Continue reading →

Giao Phan, MD, FACS [View Image]

Massey opens clinical trial testing a new immunotherapy for metastatic melanoma

VCU Massey Cancer Center is one of 17 global sites (and one of 14 in the U.S.) participating in a phase 2 clinical trial to evaluate the effectiveness and safety of an adoptive cell-transfer therapy to treat patients with metastatic melanoma. The trial, which uses the patient’s own tumor to grow immune cells designed to attack cancerous cells in the body, represents the first cell-based immunotherapy performed at VCU Massey Cancer Center.

Continue reading →

A common virus may help inform treatment planning for stem cell transplant patients

Most healthy people barely notice infection with the human cytomegalovirus (hCMV), a form of the herpes virus that has evolved with humans over thousands of years and usually lays dormant in the body after initial infection. Now, in a study recently published in the journal PLOS ONE, a team of scientists from VCU Massey Cancer Center have shown a genetic relationship between the reactivation of hCMV and the onset of graft-versus-host disease (GVHD), a potentially deadly condition in which the immune system attacks healthy tissue following a bone marrow or stem cell transplant.

Continue reading →

View graphic version